GeneThera Extends its Reach Overseas

Results from Pharma Finance 2009

ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC:
GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is
addressing our recent events.

GeneThera Inc. recently attended Pharma Finance 2009, a Biotechnology, Medical
Devices, and world public and private Finance Conference in Rome, Italy on
June 4-5.

Pharma Finance is an international event addressing new technologies for Life
Sciences, concentrating on Biotechnology, finance, nano-technology and
innovative materials.

The Lazio Region and Sviluppo Lazio S.p.A. jointly organized Pharma Finance,
in collaboration with the Ministry for International Commerce, ICE, Filas
S.p.A. and the Zangani Investor Community.

During the two-day event big pharma, small and medium size enterprises,
research and university centers presented their products, research projects
and technologies. The Conference foreign delegation session fostered the
internationalization process taken by many businesses, to develop
international cooperation; the presence of Business Angels and Venture
Capitalist provided useful information to new entrepreneurial activities.

Dr. Milici comments, "We felt that this particular conference provided us the
opportunity to meet with companies outside the United States, such as Canada
and Italy, but also emerging nations such as The United Arab Emirates and
Singapore to name a few. We feel that the safety of the world's food system
can be protected by our proprietary technology, which stems from our vast
expertise in creating solutions from microbiology and genetics."

As a result of the attendance at Pharma Finance 2009, GeneThera is in talks
with the University of Rome, who is also working on a vaccine for Johne's
disease and looking to collaborate on the activities in Mexico. In addition,
GeneThera will be looking to expand its investor base by applying for the TSX
Venture Exchange after speaking with the exchange's vice president.

As discussions progress, the company will release more details.

ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Arvada,
Colorado. The Company's proprietary diagnostic solution is based on a genetic
expression assay, GES, a protocol designed to function on a highly automated
Fluorogenic PCR platform. This platform enables GeneThera to offer tests that
are presently not available from other technologies. The GES is designed for a
host of individual diseases, the current priorities being Mad Cow disease, E.
coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony
Milici at 303-463-6371 or Richard Dopkin at JR Dopkin & Associates LLC at
516-884-3200.

This press release contains forward-looking statements, which are made
pursuant to the Safe-Harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "intends," "believes," and similar
expressions reflecting something other than historical fact are intended to
identify forward-looking statements, but are not the exclusive means of
identifying such statements. These forward-looking statements involve a number
of risks and uncertainties, including the timely development and market
acceptance of products and technologies, the ability to secure additional
sources of finance, the ability to reduce operating expenses, and other
factors described in the Company's filings with the Securities and Exchange
Commission. The actual results that the Company achieves may differ materially
from any forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may arise after
the date of this release.

SOURCE GeneThera, Inc.

Dr. Tony Milici, +1-303-463-6371, or JR Dopkin & Associates, +1-516-884-3200,
both for GeneThera, Inc.